In recent years, Low-dose interleukin 2 (Ld-IL2) therapy has emerged as a promising treatment for a range of autoimmune diseases, including systemic lupus erythematosus (SLE) [1], rheumatoid arthritis (RA) [2], and dermatomyositis (DM) [3]. The gene discussed is IL2; the disease is rheumatoid arthritis.